Business Context and Reporting Period
Company: BiomX Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 11, 2026
Event: Results of a Special Meeting of Stockholders adjourned from February 25, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
On March 11, 2026, BiomX Inc. held a Special Meeting to vote on proposals related to a Securities Purchase Agreement dated December 26, 2025. As of the record date (February 3, 2026), there were 1,593,516 shares of Common Stock outstanding. All proposals were approved by stockholders.
- Proposal 1: Authorization to issue shares of Common Stock underlying Series Y Convertible Preferred Stock and Warrants in an amount exceeding 19.99% of outstanding shares to comply with NYSE American listing rules.
- Voting Results for Proposal 1:
- For: 528,511
- Against: 23,714
- Abstain: 4,753
- Proposal 2: Approval to adjourn the meeting if necessary to solicit further votes for Proposal 1.
- Voting Results for Proposal 2:
- For: 524,578
- Against: 31,778
- Abstain: 622
No adjournment was necessary as Proposal 1 received sufficient votes.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the context of the equity issuance. The primary contingency addressed was the potential need to adjourn the meeting to secure approval for the equity issuance, which was not required.
Investor Verification Checklist
- Verify the terms of the Securities Purchase Agreement dated December 26, 2025, referenced in Proposal 1.
- Review the definitive proxy statement filed on February 13, 2026, for detailed descriptions of the Series Y Convertible Preferred Stock and Warrants.
- Confirm the impact of the approved issuance on existing shareholder dilution, noting the authorization exceeds 19.99% of pre-offering shares.
- Check subsequent filings for the actual issuance of the Preferred Stock and Warrants.